Filing Flows › Comparisons › EMMA vs GENB
Emmaus Life Sciences vs Generate Biomedicines: EMMA and GENB compared
Emmaus Life Sciences is the larger company: $6.3M of revenue in its latest quarter (Q2 2026) against $6.3M for Generate Biomedicines (Q2 2026). Emmaus Life Sciences is growing faster (+124% against -38% a year earlier).
Where the money goes: EMMA and GENB
Emmaus Life Sciences (EMMA) · Q2 2026
Emmaus Life Sciences, Q2 2026: revenue $6.3M (+124% year over year), operating margin 60.0%, net earnings $1.3M, operating cash flow $1.7M. The chart follows the revenue to costs, profit and cash.
Generate Biomedicines (GENB) · Q2 2026
Generate Biomedicines, Q2 2026: revenue $6.3M (-38% year over year), net loss $67.3M, operating cash flow −$57.9M. The chart follows the revenue to costs, profit and cash.
| Emmaus Life Sciences (EMMA) | Generate Biomedicines (GENB) | |
|---|---|---|
| Latest quarter | Q2 2026 | Q2 2026 |
| Revenue | $6.3M | $6.3M |
| Revenue growth, Y/Y | +124% | -38% |
| Gross margin | 94.6% | — |
| Operating margin | 60.0% | n/m |
| Net earnings | $1.3M | −$67.3M |
| Net margin | 21.2% | — |
| Operating cash flow | $1.7M | −$57.9M |
Where the revenue comes from
Emmaus Life Sciences
- Endari US: $6.0M (95%)
- Endari International: $295K (5%)
- Product and Service Other: $22K (0%)
Questions
Which is bigger, Emmaus Life Sciences or Generate Biomedicines?
Emmaus Life Sciences is the larger company: $6.3M of revenue in its latest quarter (Q2 2026) against $6.3M for Generate Biomedicines (Q2 2026).
Is Emmaus Life Sciences or Generate Biomedicines growing faster?
Emmaus Life Sciences is growing faster (+124% against -38% a year earlier).
More: Emmaus Life Sciences earnings · how Emmaus Life Sciences makes money · Generate Biomedicines earnings · how Generate Biomedicines makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Aug 14, 2026; 10-Q filed Aug 6, 2026). Fiscal quarters can end on different dates. Not investment advice.